Video Insights
Advertisement
Advertisement
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
A US population-based study investigated the associations between MGUS and various dietary patterns.
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
In this DLBCL roundtable, experts share which novel agents or combinations they are most interested in.
Ruemu Birhiray, MD, leads an expert roundtable on the current treatment pathway in DLBCL.
The expert panel assesses the current and expected utility for clinicians of MRD in DLBCL management decisions.
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Resistance remains a challenge in central nervous system lymphoma, creating a need for novel therapeutic combinations.
The TakeAim study explores dual inhibition with BTK and IRAK4 inhibitors.
Grzegorz Nowakowski discusses the challenges and advances in central nervous system lymphoma treatment.
Nicole Grieselhuber, MD, PhD on results of SEA-CD70 treatment in patients with high-risk MDS.
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
An expert panel delves into new data regarding the long-term efficacy of luspatercept in MDS.
An expert MDS panel discusses patient reported outcomes, transfusion dependence, and time toxicity.
Michael Tomasson, MD, discusses combining elranatamab with carfilzomib and dexamethasone in multiple myeloma.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
Two experts discuss the role of surrogate end points in MPN clinical trials.
Dr. Patel discusses PFS and MRD negativity results from the CARTITUDE-4 trial of cilta-cel versus standard of care in MM.
Researchers have developed a new scoring system using one of the largest global cohorts of T-cell lymphoma patients.
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Dr. Callander discusses a study on selinexor, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
The panel discussed novel targeted combinations in CNS lymphoma, such as BTK inhibitors in combination with IRAK inhibitors.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.